HUMAN INSULIN FROM RECOMBINANT DNA TECHNOLOGY
HUMAN INSULIN FROM RECOMBINANT DNA TECHNOLOGY
复制标题
DOI：
10.1126/science.6337396
复制
发表时间：
1983-01-01
期刊：
影响因子：
56.9
通讯作者：
JOHNSON, IS
中科院分区：
文献类型：
--
作者：
JOHNSON, IS
利用重组DNA技术生产的人胰岛素是第一个由该技术衍生的商业保健品。在大规模重组DNA工作或重组DNA产品的商业开发的联邦指南出台之前，就开始了对该产品的研究。介绍了为便于接受大规模工作和证明此类产品的身份和安全性而采取的步骤。虽然重组DNA技术的基础研究将继续对生命科学的研究产生深远的影响，但商业应用很可能受到经济条件和投资资本可得性的控制。
Human insulin produced by recombinant DNA technology is the first commercial health care product derived from this technology. Work on this product was initiated before there were federal guidelines for large-scale recombinant DNA work or commercial development of recombinant DNA products. The steps taken to facilitate acceptance of large-scale work and proof of the identity and safety of such a product are described. While basic studies in recombinant DNA technology will continue to have a profound impact on research in the life sciences, commercial applications may well be controlled by economic conditions and the availability of investment capital.